Michael Barbella, Managing Editor11.20.23
Viz.ai is touting new clinical data supporting advancements in pulmonary embolism (PE) detection. Two studies demonstrate the real-world clinical efficacy of Viz.ai’s PE Module to quickly and accurately identify PE and associated right heart strain, accelerate care coordination, and improve healthcare workflow efficiency.
The first study, “Automated PE Clot Detection and RV/LV Ratio Measurement using AI-based Deep Learning Algorithms: A Preliminary Validation Study,” evaluated the performance of Viz PE and Viz Right Ventricle/Left Ventricle (RV/LV) algorithms. Data show Viz PE demonstrated a sensitivity of 91.1% and specificity of 100% across 100 retrospectively-collected chest CTPA images. Furthermore, the analysis revealed a significant positive correlation between algorithmic and manual calculation of RV/LV ratio.
“Our preliminary findings underscore the remarkable performance of Viz PE and Viz RV/LV,” said Parth Rali, M.D., associate professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. “We are excited to partner with Viz.ai and pioneer investigator-initiated research that will reveal the impact of AI technology in revolutionizing patient care.”
The second study, “The Use of Artificial Intelligence Technology in the Detection and Treatment of Pulmonary Embolism at a Tertiary Referral Center,” demonstrated the ways in which Viz PE directly improves patient wait times for evaluation. Adoption of Viz.ai’s technology significantly reduced time to consult on average from four hours to six minutes, leading to faster diagnosis and initiation of treatment, the data indicate. When combined with multidisciplinary evaluation by an existing Pulmonary Embolism Response Team (PERT), time to radiology report was reduced by 109 minutes, showcasing the potential combined benefits of AI technology and the PERT model of care on PE care and management.
“The integration of AI technology into our PE workflow has significantly shortened the time-to-consult, helping us to promptly evaluate and triage these potentially unstable patients,” said Jacob Shapiro, M.D., vascular surgery resident at TriHealth. “This advancement has the possibility to reshape the landscape of PE management.”
Pulmonary embolism is a severe medical condition, which affects around 900,000 U.S. residents annually, and is often challenging to diagnose and treat due to overlapping symptoms with other diseases.
“These research studies mark a significant step forward in the utilization of AI technology for PE detection, reaffirming Viz.ai’s commitment to improving patient care and outcomes,” stated Molly Madziva Taitt, Ph.D., vice president of Global Clinical Affairs at Viz.ai. “The potential of the AI-powered Viz PE Solution to enhance early detection of PE and associated right heart strain, coupled with streamlined clinical workflow, holds promise for both healthcare professionals and patients worldwide.”
Viz.ai uses AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400-plus hospitals and health systems in the United States and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers value to patients, providers, and pharmaceutical and medical device companies.
The first study, “Automated PE Clot Detection and RV/LV Ratio Measurement using AI-based Deep Learning Algorithms: A Preliminary Validation Study,” evaluated the performance of Viz PE and Viz Right Ventricle/Left Ventricle (RV/LV) algorithms. Data show Viz PE demonstrated a sensitivity of 91.1% and specificity of 100% across 100 retrospectively-collected chest CTPA images. Furthermore, the analysis revealed a significant positive correlation between algorithmic and manual calculation of RV/LV ratio.
“Our preliminary findings underscore the remarkable performance of Viz PE and Viz RV/LV,” said Parth Rali, M.D., associate professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. “We are excited to partner with Viz.ai and pioneer investigator-initiated research that will reveal the impact of AI technology in revolutionizing patient care.”
The second study, “The Use of Artificial Intelligence Technology in the Detection and Treatment of Pulmonary Embolism at a Tertiary Referral Center,” demonstrated the ways in which Viz PE directly improves patient wait times for evaluation. Adoption of Viz.ai’s technology significantly reduced time to consult on average from four hours to six minutes, leading to faster diagnosis and initiation of treatment, the data indicate. When combined with multidisciplinary evaluation by an existing Pulmonary Embolism Response Team (PERT), time to radiology report was reduced by 109 minutes, showcasing the potential combined benefits of AI technology and the PERT model of care on PE care and management.
“The integration of AI technology into our PE workflow has significantly shortened the time-to-consult, helping us to promptly evaluate and triage these potentially unstable patients,” said Jacob Shapiro, M.D., vascular surgery resident at TriHealth. “This advancement has the possibility to reshape the landscape of PE management.”
Pulmonary embolism is a severe medical condition, which affects around 900,000 U.S. residents annually, and is often challenging to diagnose and treat due to overlapping symptoms with other diseases.
“These research studies mark a significant step forward in the utilization of AI technology for PE detection, reaffirming Viz.ai’s commitment to improving patient care and outcomes,” stated Molly Madziva Taitt, Ph.D., vice president of Global Clinical Affairs at Viz.ai. “The potential of the AI-powered Viz PE Solution to enhance early detection of PE and associated right heart strain, coupled with streamlined clinical workflow, holds promise for both healthcare professionals and patients worldwide.”
Viz.ai uses AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400-plus hospitals and health systems in the United States and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers value to patients, providers, and pharmaceutical and medical device companies.
